Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China

被引:44
作者
Li, Xia
Zhang, Ying
Shen, Xin
Shen, Guomiao
Gui, Xiaohong
Sun, Bin
Mei, Jian
DeRiemer, Kathryn
Small, Peter M.
Gao, Qian
机构
[1] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China
[3] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China
[4] Shanghai Municipal Ctr Dis Control & Prevent, Dept TB Control, Shanghai, Peoples R China
[5] Univ Calif Davis, Sch Med, Davis, CA 95616 USA
[6] Inst Syst Biol, Seattle, WA USA
[7] Bill & Melinda Gates Fdn, Seattle, WA USA
关键词
D O I
10.1086/511985
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We sought to determine whether patients who had therapy failure with increasingly drug-resistant strains of tuberculosis had primary or acquired drug resistance, by genotyping the initial and subsequent drug-resistant clinical isolates of Mycobacterium tuberculosis collected from patients by the Shanghai Centers for Disease Control and Prevention over the course of a 5-year period. The vast majority of patients (27/32) had primary drug resistance, indicating transmission of a drug-resistant strain of M. tuberculosis. Only 16% (5/32) had acquired drug resistance because of a poor treatment regimen or nonadherence to an adequate regimen. Our findings highlight the urgency of increasing efforts to interrupt the transmission of drug-resistant tuberculosis in communities and facilities in Shanghai, China.
引用
收藏
页码:864 / 869
页数:6
相关论文
共 20 条
[1]  
[Anonymous], 2006, Lancet, V368, P964
[2]  
Baldeviano-Vidalón GC, 2005, INT J TUBERC LUNG D, V9, P1155
[3]  
CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21
[4]  
Chen XY, 2004, LANCET, V364, P417
[5]  
Cohen J, 2006, SCIENCE, V313, P1554
[6]   Classification of drug-resistant tuberculosis [J].
DeRiemer, K ;
García, MDG ;
Garduño, APD ;
Osornio, JS ;
Small, PM .
LANCET, 2000, 356 (9245) :1931-1932
[7]   Global trends in resistance to antituberculosis drugs [J].
Espinal, MA ;
Laszlo, A ;
Simonsen, L ;
Boulahbal, F ;
Kim, SJ ;
Reniero, A ;
Hoffner, S ;
Rieder, HL ;
Binkin, N ;
Dye, C ;
Williams, R ;
Raviglione, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (17) :1294-1303
[8]   Exogenous reinfection in tuberculosis [J].
Fine, PEM ;
Small, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (16) :1226-1227
[9]   Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis [J].
Krüüner, A ;
Pehme, L ;
Ghebremichael, S ;
Koivula, T ;
Hoffner, SE ;
Mikelsaar, M .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (02) :146-155
[10]   Evaluation of the epidemiologic utility of secondary typing methods for differentiation of Mycobacterium tuberculosis isolates [J].
Kwara, A ;
Schiro, R ;
Cowan, LS ;
Hyslop, NE ;
Wiser, MF ;
Harrison, SR ;
Kissinger, P ;
Diem, L ;
Crawford, JT .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (06) :2683-2685